How durable are the responses of CLL patients to therapy?
Potential concerns with ventoclax and Richter's transformation
The differences in treating older versus younger CLL patients
Immunotherapy highlights in multiple myeloma at ASH 2016
Niels van de Donk
Diffuse large B-cell lymphoma lymphoma: Finding the best partner for durvalumab